🏛️ Verified NIH Record • Updated 2025-04-18
Study of REM-422 in Patients With AML or Higher Risk MDS (NCT06297941)
A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS
🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Remix Therapeutics
🩺 Plain-English Summary (8th-Grade Level)
The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (9 Sites)
- City of Hope — Duarte, California
- Moffitt Cancer Center — Tampa, Florida
- Massachusetts General Hospital — Boston, Massachusetts
- Memorial Sloan Kettering — New York, New York
- MD Anderson Cancer Center — Houston, Texas
- Centre Hospitalier Universitaire (CHU) de Bordeaux — Bordeaux,
- AP-HP - Hôpital Saint-Louis — Paris,
- IUCT-Oncopole — Toulouse,
- Institut de Cancerologie Gustave-Roussy — Villejuif,
📞 Contact the Study Coordinator
Phone: (781) 827-0902
Email: ClinicalTrials@remixtx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Myelodysplastic Syndromes
- ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions — Clovis, California
- Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA — Tampa, Florida
- A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) — Lakewood, California
- Inqovi Maintenance Therapy in Myeloid Neoplasms — Boston, Massachusetts
- Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) — Birmingham, Alabama
- CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome — Tampa, Florida
Explore by condition: All Myelodysplastic Syndromes clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.